NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Piper Sandler Starts Coverage on Shattuck Labs with Bullish View

Piper Sandler begins coverage of Shattuck Labs with an Overweight rating and $15 target, highlighting promise of SL-325 ahead of Phase 1 data.

Piper Sandler Starts Coverage on Shattuck Labs with Bullish View
Credit: Shattuck Labs
Already have an account? Sign in.
01/28/2026 · 11:01 AM
STTK
/ Don’t stop at just one post.

Related↓

Shattuck Labs Stock Gets Bullish Citi Upgrade Before SL-325 Phase 1 Results
06/05/2026 · 7:10 AM

Shattuck Labs Stock Gets Bullish Citi Upgrade Before SL-325 Phase 1 Results

Citi upgrades STTK to Buy with $7 price target and 30-day upside watch ahead of SL-325 Phase 1 data in Q2 2026.

/ Subscriber only
/ Read more

Feed↓

Morgan Stanley Upgrades Grindr to Overweight, Sees 25% Upside on AI and Telehealth Push
07/01/2026 · 4:01 PM

Morgan Stanley Upgrades Grindr to Overweight, Sees 25% Upside on AI and Telehealth Push

New Edge AI tier and Woodwork telehealth expected to drive strong revenue growth.

/ Subscriber only
TD Cowen Boosts TransMedics Price Target to $120 on Strong Transplant Growth
07/01/2026 · 3:38 PM

TD Cowen Boosts TransMedics Price Target to $120 on Strong Transplant Growth

Accelerating U.S. heart, liver & lung transplants plus strong flight data signal major growth ahead.

/ Subscriber only
Short Seller Culper Attacks Tarsus Pharmaceuticals Over XDEMVY Market Size
07/01/2026 · 1:21 PM

Short Seller Culper Attacks Tarsus Pharmaceuticals Over XDEMVY Market Size

Culper Research argues Tarsus is significantly overvalued, disputing the addressable market for its Demodex blepharitis drug XDEMVY.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe